Your browser doesn't support javascript.
loading
Late cardiac death in patients undergoing transcatheter aortic valve replacement: incidence and predictors of advanced heart failure and sudden cardiac death.
Urena, Marina; Webb, John G; Eltchaninoff, Helene; Muñoz-García, Antonio J; Bouleti, Claire; Tamburino, Corrado; Nombela-Franco, Luis; Nietlispach, Fabian; Moris, Cesar; Ruel, Marc; Dager, Antonio E; Serra, Vicenç; Cheema, Asim N; Amat-Santos, Ignacio J; de Brito, Fabio Sandoli; Lemos, Pedro Alves; Abizaid, Alexandre; Sarmento-Leite, Rogério; Ribeiro, Henrique B; Dumont, Eric; Barbanti, Marco; Durand, Eric; Alonso Briales, Juan H; Himbert, Dominique; Vahanian, Alec; Immè, Sebastien; Garcia, Eulogio; Maisano, Francesco; del Valle, Raquel; Benitez, Luis Miguel; García del Blanco, Bruno; Gutiérrez, Hipólito; Perin, Marco Antonio; Siqueira, Dimytri; Bernardi, Guilherme; Philippon, François; Rodés-Cabau, Josep.
Afiliação
  • Urena M; Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.
  • Webb JG; St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
  • Eltchaninoff H; Hôpital Charles Nicolle, University of Rouen, Rouen, France.
  • Muñoz-García AJ; Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.
  • Bouleti C; Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France.
  • Tamburino C; Ferrarotto Hospital, University of Catania, Catania, Italy.
  • Nombela-Franco L; Hospital Universitario Clínico San Carlos, Madrid, Spain.
  • Nietlispach F; University Heart Center, Transcatheter Valve Clinic, University Hospital Zurich, Zurich, Switzerland.
  • Moris C; Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Ruel M; Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada.
  • Dager AE; Clìnica de Occidente de Cali, Valle del Cauca, Colombia.
  • Serra V; Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.
  • Cheema AN; St. Michael's Hospital, Toronto University, Toronto, Ontario, Canada.
  • Amat-Santos IJ; Hospital Clinico Universitario de Valladolid, Valladolid, Spain.
  • de Brito FS; Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Lemos PA; Heart Institute-InCor, University of São Paulo, São Paulo, Brazil.
  • Abizaid A; Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.
  • Sarmento-Leite R; Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, Brazil.
  • Ribeiro HB; Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.
  • Dumont E; Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.
  • Barbanti M; St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada; Ferrarotto Hospital, University of Catania, Catania, Italy.
  • Durand E; Hôpital Charles Nicolle, University of Rouen, Rouen, France.
  • Alonso Briales JH; Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.
  • Himbert D; Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France.
  • Vahanian A; Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France.
  • Immè S; Ferrarotto Hospital, University of Catania, Catania, Italy.
  • Garcia E; Hospital Universitario Clínico San Carlos, Madrid, Spain.
  • Maisano F; University Heart Center, Transcatheter Valve Clinic, University Hospital Zurich, Zurich, Switzerland.
  • del Valle R; Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Benitez LM; Clìnica de Occidente de Cali, Valle del Cauca, Colombia.
  • García del Blanco B; Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.
  • Gutiérrez H; Hospital Clinico Universitario de Valladolid, Valladolid, Spain.
  • Perin MA; Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Siqueira D; Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.
  • Bernardi G; Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, Brazil.
  • Philippon F; Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.
  • Rodés-Cabau J; Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada. Electronic address: josep.rodes@criucpq.ulaval.ca.
J Am Coll Cardiol ; 65(5): 437-48, 2015 Feb 10.
Article em En | MEDLINE | ID: mdl-25660921
BACKGROUND: Little evidence exists of the burden and predictors of cardiac death after transcatheter aortic valve replacement (TAVR). OBJECTIVES: The purpose of this study was to assess the incidence and predictors of cardiac death from advanced heart failure (HF) and sudden cardiac death (SCD) in a large patient cohort undergoing TAVR. METHODS: The study included a total of 3,726 patients who underwent TAVR using balloon (57%) or self-expandable (43%) valves. Causes of death were defined according to the Valve Academic Research Consortium-2. RESULTS: At a mean follow-up of 22 ± 18 months, 155 patients had died due to advanced HF (15.2% of total deaths, 46.1% of deaths from cardiac causes) and 57 had died due to SCD (5.6% of deaths, 16.9% of cardiac deaths). Baseline comorbidities (chronic obstructive pulmonary disease, atrial fibrillation, left ventricular ejection fraction ≤40%, lower mean transaortic gradient, pulmonary artery systolic pressure >60 mm Hg; p < 0.05 for all) and 2 procedural factors (transapical approach, hazard ratio [HR]: 2.38, 95% confidence interval [CI]: 1.60 to 3.54; p < 0.001; presence of moderate or severe aortic regurgitation after TAVR, HR: 2.79, 95% CI: 1.82 to 4.27; p < 0.001) independently predicted death from advanced HF. Left ventricular ejection fraction ≤40% (HR: 1.93, 95% CI: 1.05 to 3.55; p = 0.033) and new-onset persistent left bundle-branch block following TAVR (HR: 2.26, 95% CI: 1.23 to 4.14; p = 0.009) were independently associated with an increased risk of SCD. Patients with new-onset persistent left bundle-branch block and a QRS duration >160 ms had a greater SCD risk (HR: 4.78, 95% CI: 1.56 to 14.63; p = 0.006). CONCLUSIONS: Advanced HF and SCD accounted for two-thirds of cardiac deaths in patients after TAVR. Potentially modifiable or treatable factors leading to increased risk of mortality for HF and SCD were identified. Future studies should determine whether targeting these factors decreases the risk of cardiac death.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Complicações Pós-Operatórias / Morte Súbita Cardíaca / Substituição da Valva Aórtica Transcateter / Insuficiência Cardíaca Tipo de estudo: Clinical_trials / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Complicações Pós-Operatórias / Morte Súbita Cardíaca / Substituição da Valva Aórtica Transcateter / Insuficiência Cardíaca Tipo de estudo: Clinical_trials / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article